科研动态期刊摘要

[文章] 在心血管风险增加的肥胖成人中评估survodutide的心血管结局(SYNCHRONIZE-CVOT):一项双盲、随机、安慰剂对照的3期试验

The Lancet Online First · 2026-11-11

完整摘要 · 中文译文

背景:Survodutide是一种胰高血糖素受体和GLP-1受体双重激动剂,可改善肥胖患者的心血管代谢健康指标,但这一新类别药物的心血管安全性仍有待确立。 方法:SYNCHRONIZE-CVOT是一项全球性、3期、随机、双盲、平行分组、安慰剂对照、多中心、事件驱动的心血管安全性试验,在34个国家的524个临床中心开展。我们纳入年龄18岁及以上、BMI为27 kg/m2或以上且已确诊心血管疾病或至少有两种肥胖并发症或心血管疾病危险因素的参与者;患有慢性肾病的参与者若同时BMI为30 kg/m2或以上也符合条件。参与者通过交互式应答技术按1:1:1随机分配至每周一次皮下注射survodutide(上调滴定至3·6 mg或6·0 mg)或安慰剂。主要终点为心血管原因死亡、非致死性卒中、非致死性心肌梗死、缺血相关冠状动脉血运重建或心力衰竭事件的复合终点(目标为189个主要终点事件)。我们评估了合并survodutide组与安慰剂组相比的非劣效性,非劣效性界值为风险比(HR)双侧95% CI上限1·65。疗效和安全性分析纳入所有随机分配且至少接受一剂survodutide或安慰剂的参与者。主要分析按治疗方案估计目标进行,该估计目标评估治疗效果时不考虑survodutide或安慰剂的任何提前停药、暂时停药、使用方案禁止的肥胖药物或延长剂量递增期。该已完成试验已在ClinicalTrials.gov注册,注册号为NCT06077864。 研究结果:从2023年11月20日至2024年11月8日,我们筛选了7753名参与者,其中5530名(71.3%)参与者被招募并随机分配接受治疗。23名(0.4%)参与者未接受治疗;5507名参与者中1836名(33.3%)接受survodutide 3.6 mg,1835名(33.3%)接受6.0 mg,1836名(33.3%)接受安慰剂;2194名(39.8%)为女性,3313名(60.2%)为男性,4332名(78.7%)为白人。研究中位时间为22.0个月(IQR 20.1-23.7)。survodutide 3.6 mg组1029名(56.0%)、survodutide 6.0 mg组1039名(56.6%)、安慰剂组1083名(59.0%)参与者持续接受治疗至研究结束。主要终点在survodutide组3671名参与者中发生136例(3.7%),在安慰剂组1836名参与者中发生76例(4.1%)(HR 0.89 [95% CI 0.67-1.18;非劣效性p<0.0001])。不良事件在survodutide 3.6 mg组1836名参与者中发生1708例(93.0%),survodutide 6.0 mg组1835名中发生1708例(93.1%),安慰剂组1836名中发生1571例(85.6%)。survodutide组胃肠道不良事件较安慰剂组更频繁(恶心在3.6 mg组1836名参与者中发生882例[48.0%]、6.0 mg组1835名中发生900例[49.0%],而安慰剂组1836名中发生223例[12.1%];呕吐在3.6 mg组发生582例[31.7%]、6.0 mg组发生623例[34.0%],而安慰剂组发生89例[4.8%])。导致治疗终止的胃肠道不良事件在survodutide 3.6 mg组发生354例(19.3%)、survodutide 6.0 mg组发生381例(20.8%)、安慰剂组发生34例(1. 安慰剂组为9%)。各治疗组严重不良事件发生率相似(survodutide 3·6 mg组413例[22·5%],survodutide 6·0 mg组381例[20·8%],安慰剂组439例[23·9%])。各治疗组致死性不良事件相似(survodutide 3·6 mg组16例[0·9%],survodutide 6·0 mg组16例[0·9%],安慰剂组11例[0·6%]),主要归因于心脏疾病(survodutide 3·6 mg组6例[0·3%],survodutide 6·0 mg组7例[0·4%],安慰剂组6例[0·3%])。 解释:在已确诊心血管疾病或慢性肾脏病、或心血管疾病风险升高的肥胖参与者中,与安慰剂相比,survodutide与心血管原因死亡、非致死性卒中、非致死性心肌梗死、缺血相关冠状动脉血运重建或心力衰竭事件这一主要复合终点的风险增加无关。这项心血管安全性试验为临床医生提供了令人安心的数据,即使用survodutide(一种新型胰高血糖素受体-GLP-1受体双重激动剂)治疗与心血管风险增加无关。 资助:勃林格殷格翰。

完整摘要 · 英文原文

BACKGROUND: Survodutide, a glucagon receptor and GLP-1 receptor dual agonist, improved markers of cardiometabolic health in people with obesity, but cardiovascular safety for this new class remains to be established. METHODS: SYNCHRONIZE-CVOT was a global, phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre, event-driven, cardiovascular safety trial conducted at 524 clinical sites in 34 countries. We included participants aged 18 years or older with a BMI of 27 kg/m2 or greater and established cardiovascular disease or at least two obesity complications or risk factors for cardiovascular disease; participants with chronic kidney disease were eligible if they also had a BMI of 30 kg/m2 or greater. Participants were randomly assigned by interactive response technology (1:1:1) to once-weekly subcutaneous survodutide (up-titrated to 3·6 mg or 6·0 mg) or placebo. The primary endpoint was a composite of death from cardiovascular causes, non-fatal stroke, non-fatal myocardial infarction, ischaemia-related coronary revascularisation, or heart failure event (targeting 189 primary endpoint events). We assessed the non-inferiority of pooled survodutide compared with placebo with a margin of 1·65 for the upper limit of the two-sided 95% CI of the hazard ratio (HR). Efficacy and safety analyses included all randomly assigned participants who received at least one dose of survodutide or placebo. The primary analysis was performed according to the treatment-regimen estimand, which assessed treatment effects regardless of any early discontinuation of survodutide or placebo, temporary stop, the use of protocol-prohibited obesity medications, or a prolonged dose-escalation period. This completed trial is registered with ClinicalTrials.gov, NCT06077864. FINDINGS: From Nov 20, 2023, to Nov 8, 2024, we screened 7753 participants, of whom 5530 (71·3%) participants were recruited and randomly assigned to treatment. 23 (0·4%) participants were not treated; 1836 (33·3%) of 5507 participants received survodutide 3·6 mg, 1835 (33·3%) received 6·0 mg, and 1836 (33·3%) received placebo; 2194 (39·8%) were female, 3313 (60·2%) were male, and 4332 (78·7%) were White. Median time in study was 22·0 months (IQR 20·1-23·7). 1029 (56·0%) in the survodutide 3·6 mg group, 1039 (56·6%) in the survodutide 6·0 mg group, and 1083 (59·0%) in the placebo group remained on treatment until study closeout. The primary endpoint occurred in 136 (3·7%) of 3671 participants in the survodutide group and in 76 (4·1%) 1836 participants in the placebo group (HR 0·89 [95% CI 0·67-1·18; p<0·0001 for non-inferiority). Adverse events occurred in 1708 (93·0%) of 1836 participants with survodutide 3·6 mg, 1708 (93·1%) of 1835 with survodutide 6·0 mg, and 1571 (85·6%) of 1836 with placebo. Gastrointestinal adverse events were more frequent with survodutide than in the placebo group (nausea occurred in 882 [48·0%] of 1836 participants in the 3·6 mg group and 900 [49·0%] of 1835 in the 6·0 mg group vs 223 [12·1%] of 1836 in the placebo group, and vomiting occurred in 582 [31·7%] participants in the 3·6 mg group and 623 [34·0%] in the 6·0 mg group vs 89 [4·8%] in the placebo group). Gastrointestinal adverse events leading to treatment discontinuations occurred in 354 (19·3%) participants in the survodutide 3·6 mg group, 381 (20·8%) in the survodutide 6·0 mg, and 34 (1·9%) in the placebo group. Serious adverse events occurred at similar rates across treatment groups (413 [22·5%] in the survodutide 3·6 mg group, 381 [20·8%] in the survodutide 6·0 mg, and 439 [23·9%] in the placebo group). Fatal adverse events were similar across treatment groups (16 [0·9%] in the survodutide 3·6 mg group, 16 [0·9%] in the survodutide 6·0 mg, and 11 [0·6%] in the placebo group) and were primarily due to cardiac disorders (six [0·3%] in the survodutide 3·6 mg group, seven [0·4%] in the survodutide 6·0 mg, and six [0·3%] in the placebo group). INTERPRETATION: In participants with obesity with established cardiovascular disease or chronic kidney disease or at increased risk of cardiovascular disease, survodutide was not associated with increased risk for the primary composite endpoint of death from cardiovascular causes, non-fatal stroke, non-fatal myocardial infarction, ischaemia-related coronary revascularisation, or heart failure event compared with placebo. This cardiovascular safety trial provides clinicians with reassuring data that treatment with survodutide, a novel glucagon receptor-GLP-1 receptor dual agonist, is not associated with increased cardiovascular risk. FUNDING: Boehringer Ingelheim.

English
[Articles] Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界